Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (112)	6/19/1998 11:18:00 PM
From: Miljenko Zuanic	Read Replies (3) \| Respond to of 626

Let's go Novartis!!! Zeldox is down: biz.yahoo.com And only Ziprexa and Risperdan is on your way. I guess, You do want to return favour to LLY, after they seized Olanzapine (Clozapine sister) in front of your nose. Regards, Miljenko PS: If You need few kg of bulk drug I can make it quickly for you, normally in return for bunch of the TTNP shares.

To: scaram(o)uche who wrote (112)	7/16/1998 8:01:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 626

Richard, due to the respect that Rainier shows in you and your obvious credentials, I would sincerely appreciate your further critique. I'm a clinical analyst, but am obviously nowhere close to your league. Today's release about the vaccines gave some more specifics of the method of action than than others before. Perhaps this addresses your concerns, perhaps not. Could you possibly comment? <<Dr. Bucalo continued, ''We believe that previously reported Phase I/II clinical testing of Titan's therapeutic cancer vaccines has demonstrated very compelling data regarding strong immune responses elicited with our vaccines. In order for cancer vaccines to have a reasonable basis for a therapeutic benefit, these types of products should generate tumor antigen specific immune responses in the large majority of patients. In addition to being tumor antigen specific, the antibody responses should be sustained and polyclonal, encompassing both IgG and IgM subtypes. This is important, because while IgM allows the potential for complement mediated tumor destruction, IgG enables cell mediated tumor killing, and it is important to enable both potential mechanisms of tumor killing. In addition, there should be evidence of T-cell activation which is again specific to the tumor antigen. In studies performed to date, Titan's vaccines are distinguished by fulfilling all these criteria.''>> Also, I thought the design of the study was fairly good, and your comments on this issue would be welcome. Miljenko, I would also greatly appreciate your insight, and understand your efforts to balance investment and family needs. Scott